BiotechTube

R-Pdf/Gbb 0.01% gel

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns, Electric Burns

Trial Timeline

Jul 1, 2011 → Apr 1, 2012

NCT ID
NCT00812513

About R-Pdf/Gbb 0.01% gel

R-Pdf/Gbb 0.01% gel is a phase 2 stage product being developed by Johnson & Johnson for Burns. The current trial status is unknown. This product is registered under clinical trial identifier NCT00812513. Target conditions include Burns, Electric Burns.

What happened to similar drugs?

3 of 6 similar drugs in Burns were approved

Approved (3) Terminated (3) Active (3)
✅Ceftolozane/tazobactamMerckApproved
✅Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
✅Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
🔄Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00812513Phase 2UNKNOWN

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
Ceftolozane/tazobactamMerckApproved
35
linezolidPfizerPhase 1
29
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
37
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
32
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
I-020502BaxterPhase 2
32
Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
25
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30